ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Hospital at home enables safe and efficient outpatient management of intensively treated acute myeloid leukemia.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePatients with acute myeloid leukemia (AML) spend a substantial amount of time in hospital while receiving intensive chemotherapy, affecting their quality of life and healthcare costs. This study evaluated the safety of outpatient management of febrile neutropenia with support from hospital at home (HaH).
methodTwo cohorts of intensively treated patients with AML were retrospectively compared, one from Stockholm (n = 116) with access to HaH and another from Gothenburg (n = 49) without HaH support. Primary outcome was incidence of severe complications, defined as death or requirement of higher level of care.
resultsDuring cycle 1 (C1), 109 of 116 patients (94%) in Stockholm were discharged, of whom 50 (46%) were readmitted. In Gothenburg, 48 of 49 patients (98%) remained in hospital for the entirety of the neutropenic phase. The incidence of severe complications, including fatal events and requirement of higher level of care, was comparable in the two cohorts. Out of 150 neutropenic episodes (during C1 and C2) among discharged Stockholm patients, febrile neutropenia developed in 130 cases (86.7%). Of these, 38 episodes (29%) were resolved with administration of antibiotics at home only.
conclusionThese findings demonstrate that outpatient management of AML patients treated with intensive chemotherapy is feasible and safe when supported by a structured HaH program in close collaboration with the hematology department. Implementation of at-home care has the potential to reduce the burden of prolonged periods of hospitalization for patients with AML and warrants further evaluation in prospective trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.